Abstract 578P
Background
Early evidence suggested a role of tissue-resident microbiota (TRM) in the development of colorectal cancer. However, its presence in colorectal cancer metastases (CRCM) is poorly reported. Here, we aim to explore and characterize the TRM in CRCM.
Methods
From several biobanks in Belgium, we retrospectively collected 237 frozen samples, including 104 CRC primary tumor (PT) and 133 patient-matched CRCM (liver CRCM=98). Hepatocellular carcinoma (HCC, n=50), cholangiocarcinoma (CGC, n=23) and breast liver metastases (BLM, n = 16) were also collected. 82 CRCM were collected prospectively. The V4 region 16S rRNA gene was amplified and sequenced. We strictly applied sterile conditions from sample collection to sequencing, with the integration of negative controls (n=253). Additionally, 257 duplicated random samples were processed twice by independent experimenters. Sequencing results were processed with DADA2 to identify bacterial amplicon sequence variants (ASVs).
Results
ASVs were identified in all tissues. Microbial composition was significantly different between tumor samples and negative controls (PERMANOVA, p=0.0001). PT presented the highest bacterial biomass. ASV sharing frequency between PT and CRCM was significantly higher within than between patients (Wilcoxon test, p=0.007), suggesting potential bacterial translocation from PT to CRCM. The most prevalent PT bacteria were also the most shared in matched CRCM. No difference was observed between CRCM locations (liver, others). TRM of HCC, CGC and BLM were characterized by an ultra-low bacterial biomass, and distinct phyla compared to CRCM. In CRCM, the presence of Ruminoccocus gnavus (Rg) was associated with overall survival after CRCM resection (median 83.6 vs 41.6 months, HR: 0.35 IC95:0.13-0.90, p=0.024).
Conclusions
We observe a specific TRM in CRCM, shared with matched PT and suggesting bacterial translocation from PT to CRCM. In this cohort, the presence of Rg in CRCM seems prognostic after CRCM resection. Further experiments are needed to confirm and detail these results.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
M. van den Eynde.
Funding
Fondation contre le cancer, Belgique.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
592P - The role of early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer
Presenter: Jinjia Chang
Session: Poster session 10
594P - The efficacy of anti-EGFR therapy for RAS mutant metastatic colorectal cancer (mCRC) patients with RAS mutation negative in circulating-tumor DNA (ctDNA) after 1st- or 2nd-line chemotherapy
Presenter: Naoki Izawa
Session: Poster session 10
595P - The DUREC trial: Durvalumab plus total neoadjuvant therapy in locally advanced rectal cancer - a multicenter, single-arm, phase II study (GEMCAD-1703)
Presenter: Jaume Capdevila Castillon
Session: Poster session 10
597P - Surgical quality for patients (pts) treated with neoadjuvant chemotherapy vs chemoradiation for locally advanced rectal cancer (LARC): PROSPECT (NCCTG N1048, alliance)
Presenter: Martin Weiser
Session: Poster session 10
598P - Influence of the early stoma closure after low rectal cancer resection on completeness of adjuvant chemotherapy (CoCStom): A randomized, controlled multicentre trial of the AIO (AIO KRK 0113)
Presenter: Flavius Sandra-Petrescu
Session: Poster session 10
599P - R-IMMUNE: A phase Ib/II study to evaluate safety and efficacy of atezolizumab combined with radio-chemotherapy in a preoperative setting for patients with locally advanced rectal cancer (LARC)
Presenter: Javier Carrasco
Session: Poster session 10